Latest news & events

NOV 23, 2015

DelMar Pharmaceuticals Updates VAL-083 Clinical Trial in Refractory Glioblastoma Multiforme at Society for Neuro-Oncology Annual Meeting

NOV 20, 2015

SNO Poster: Phase I/II Study of Dianhydrogalactitol in Patients with Recurrent Malignant Glioma

NOV 19, 2015

DelMar Pharmaceuticals to Present at the 8th Annual LD Micro Main Event on December 2, 2015

NOV 17, 2015

DelMar Pharmaceuticals Reports First Quarter Fiscal Year 2016 Financial Results and Provides Corporate Update

NOV 13, 2015

DelMar Pharmaceuticals Presents Data Summarizing the Potential of VAL-083 as a New Treatment Option for Resistant Cancers

NOV 11, 2015

DelMar Pharmaceuticals Presents Data Supporting VAL-083 as a Promising Potential Treatment for Pediatric Brain Tumors

NOV 10, 2015

DelMar Pharmaceuticals Collaborators Present Data on the Unique Molecular Mechanisms Responsible for VAL-083 Activity Against Cancer

NOV 9, 2015

DelMar Pharmaceuticals to Present Updated Phase II Safety and Efficacy Data on VAL-083 in Refractory Glioblastoma Multiforme

NOV 6, 2015

DelMar Pharmaceuticals Presents Positive Data on the Benefit of VAL-083 in Combination with Platinum-Based Chemotherapy for Non-Small Cell Lung

NOV 5, 2015

DelMar Pharmaceuticals to Present at the SeeThruEquity Microcap Investor Forum on November 12, 2015

View all news

Business Update Conference Call
November 23, 2015 • 4:30 pm ET
Playback (MP3): Click here
Presentation Slides (PDF): Click here

DelMar's fight against cancer


VAL-083, our first product candidate, represents a "first-in-class" small molecule chemotherapeutic, which means that the molecular structure of VAL-083 is not an analogue or derivative of other small molecule chemotherapeutics approved for the treatment of cancer.

Learn more about VAL-083


Our mission is to benefit patients and create shareholder value by rapidly developing and commercializing anti-cancer therapies in orphan cancer indications where patients have failed or are unlikely to respond to modern therapy.

Learn more about DelMar


Our drug discovery research focuses on identifying well-validated clinical and commercial-stage compounds and establishing a scientific rationale for development in modern orphan drug indications.

Learn more about our drug development pipeline